WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality
* WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly improve productivity and quality, and reduce cost-of-goods (COGS) in commercial manufacturin...
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), on receiving U.S. FDA's approval for Pombili...
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumor immune micr...
WuXi Biologics to Increase Manufacturing Capacity in Germany
- In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance and drug product inGermany - The investment promotes the creation of additional high-skilled jobs - As part of WuXi Biologics' global manufacturi...
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced thatthe International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facili...
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. * InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April ...
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval ...
WuXi Biologics Reports Remarkable 2022 Annual Results
Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million Adjusted Net Profit Rose by 47.1% to RMB5,053.9 Million Non-COVID Revenue Achieved 63% Y-o-Y Growth, Strong Momentum Continues into 2023 and Beyond "R" in CRDMO Business Model A...
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms * WuXi Biologics will receive an upfro...
WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List
SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...
WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China
- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global manufacturing network. This new facility enhances the company's capability of providing commercial manufacturing at 4,000L to 20,000L scale, facilitating any project initiation within four weeks. - ...
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China, Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading gl...
WuXi Biologics Receives "Best CDMO Award of the Year"
SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 202...
WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company fromKyoto University, today announced that they have signed a Memorandum of Under...
WuXi Biologics Co., Ltd. Removed from Unverified List
WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U....
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
WORCESTER, Mass., Sept. 29, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony, in partnership with the Worcester Business Development Corporation (WBDC), to mark the completion of...
WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA
WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received reg...
WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey
CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced the release of its GMP phase I drug substance clinical manufacturing facility, MFG18, inCranbury, New Jersey...
